Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from AOTI, Inc. ( (GB:AOTI) ) is now available.
AOTI, Inc. has started enrolling patients in the USA for a significant clinical trial, known as the VaLUe trial, to evaluate the effectiveness of its Topical Wound Oxygen (TWO2) therapy on chronic Venous Leg Ulcers (VLUs). These ulcers are a major healthcare challenge, affecting around 2% of the global population and leading to a high recurrence rate. The trial aims to demonstrate the durable healing efficacy of TWO2 therapy, which has already shown promising results in previous studies. This development could significantly impact VLU treatment by providing a more effective and accessible therapy option, potentially easing the burden on healthcare systems and improving patient outcomes.
More about AOTI, Inc.
AOTI, Inc., founded in 2006, is a medical technology company based in Oceanside, California, US, and Galway, Ireland. It specializes in innovative solutions for severe and chronic wounds, focusing on durable healing and prevention of amputations. The company’s patented Topical Wound Oxygen (TWO2) therapy is non-invasive and can be administered at home, reducing healthcare costs and improving patient quality of life. TWO2 therapy has proven effective in reducing the recurrence of Diabetic Foot Ulcers and has received regulatory clearance in the US, Europe, UK, and several other countries.
YTD Price Performance: -15.44%
Average Trading Volume: 23,531
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £122.3M
See more insights into AOTI stock on TipRanks’ Stock Analysis page.
